For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How has the adrenocortical carcinoma grown historically, and what trends indicate future expansion?
The adrenocortical carcinoma market size has grown steadily in recent years. It will grow from $3.60 billion in 2024 to $3.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing incidence of adrenocortical carcinoma, growing awareness of rare endocrine tumors, increased government and research funding, growing patient support and advocacy groups, and rising prevalence of rare cancers.
The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to increased use of combination therapies, rising adoption of personalized medicine approaches, expanding clinical trials, increased participation in international research networks, and increased government and research funding. Major trends in the forecast period include advancements in genomic sequencing and personalized medicine, targeted therapy innovations, immunotherapy developments, liquid biopsy technology, and advances in biomarker identification.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20705&type=smp
Which key factors are driving the expansion of the adrenocortical carcinoma industry?
The increase in prevalence rates of rare cancer is expected to propel the growth of the adrenocortical carcinoma market going forward. Rare cancers are referred to as distinguished by low incidence rates and a significant influence on patient outcomes, needing specialist techniques for diagnosis and therapy. The increase in prevalence rates of rare cancer is driven by several factors, such as developments in diagnostic methods that have enhanced the detection of adrenocortical carcinoma, enabling the early identification of instances that could have gone undetected in the past. Adrenocortical carcinoma (ACC) contributes to the increase in prevalence rates of rare cancers by being a relatively uncommon yet aggressive cancer type, highlighting the need for improved diagnosis and treatment strategies. For instance, in February 2022, according to a report by the International Agency for Research on Cancer of the World Health Organization, a Switzerland-based intergovernmental organization, nearly six new cases of rare cancers are diagnosed per 100,000 individuals in the US each year. Therefore, the increase in prevalence rates of rare cancer will drive the growth of the adrenocortical carcinoma market.
How is the adrenocortical carcinoma market segmented by product, application, and end-user?
The adrenocortical carcinoma market covered in this report is segmented –
1) By Type: Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma
2) By Therapy: Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, External Beam Radiation Therapy, Bratchytherapy, Adjuvant Therapy, Other Therapy
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Cancer Research Institutes
Subsegments:
1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma, Advanced Localized Adrenocortical Carcinoma
2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs, Local Regional Metastasis
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report
Which major trends are influencing the growth of the adrenocortical carcinoma industry?
Major companies operating in the adrenocortical carcinoma market are focusing on developing innovative therapies, such as small-molecule drugs, to target specific tumor pathways and improve patient outcomes. A small-molecule drug is a low molecular weight compound that penetrates cells to target proteins or enzymes, regulating biological processes and treating diseases such as adrenocortical carcinoma by inhibiting tumor growth pathways. For instance, in January 2023, Orphagen Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) for its investigational drug OR-449, aimed at treating pediatric adrenocortical carcinoma (ACC). This drug aims to treat pediatric ACC, a rare and aggressive cancer primarily affecting children. The disease often presents with symptoms linked to hormonal overproduction, such as virilization and Cushing syndrome. Diagnosis involves imaging and hormonal assessments, with prognosis influenced by factors such as age at diagnosis and tumor resectability.
Which leading companies are dominating the adrenocortical carcinoma market landscape?
Major companies operating in the adrenocortical carcinoma market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., Millendo Therapeutics Inc.
Which geographic areas are expected to offer the highest growth opportunities in theadrenocortical carcinoma market?
North America was the largest region in the adrenocortical carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenocortical carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Adrenocortical Carcinoma Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20705
Need Customized Data On Adrenocortical Carcinoma Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20705&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
